Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand
about
Poxvirus vectors as HIV/AIDS vaccines in humansThe evolution of poxvirus vaccinesHIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials.Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand.HIV-1 vaccines: challenges and new perspectivesNovel directions in HIV-1 vaccines revealed from clinical trialsAn HIV Vaccine for South-East Asia-Opportunities and Challenges.New prospects for a preventive HIV-1 vaccine.Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds.Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or PolyphosphazeneA systematic review of ethical issues in vaccine studies involving pregnant women.In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodiesHIV epidemic in Asia: optimizing and expanding vaccine development.Clinical applications of attenuated MVA poxvirus strain.Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation.Construction, Selection and Immunogenicity of Recombinant Fowlpox Candidate Vaccine Co-expressing HIV-1 gag and gp145.Virus-based nanoparticles as platform technologies for modern vaccines.Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains.HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial.DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model.Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.Vector order determines protection against pathogenic simian immunodeficiency virus infection in a triple component vaccine by balancing CD4+ and CD8+ T-cell responses.Recombinant fowlpox virus vector-based vaccines: expression kinetics, dissemination and safety profile following intranasal delivery.Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era.Virus-Like-Vaccines against HIV.
P2860
Q26995078-3A3DDE50-E731-42DD-BECB-9133A18A995DQ26995905-5B273637-7E2F-416E-9A21-F46AB3A37BB6Q27687375-9DB82989-BA01-4EB0-A95F-5BA3D9650F1EQ31138173-5AB26693-E736-4DA5-A119-EC37C21B483AQ33423120-C13DBDBC-F906-44D5-AC6D-F27CB705E945Q33577972-F36F5D5F-0116-459E-B4DD-AC2BA9E85817Q33645528-4B550A45-C16F-4B93-8DB8-A35E9463E56AQ35826681-E9FF6C8A-8E74-44AA-B2E0-29BDD323AAA2Q36223864-6C414CEC-83B4-4ABC-BC51-CC5AD7F262E5Q36878885-502B779B-212E-4BE6-AB14-120E01E50876Q36931790-F85DFDA9-1B80-4948-B03D-79C51588531EQ37197059-D5785019-6CA6-40D4-8622-B8774FF9584DQ37547141-00F8888D-1148-45A0-8D9C-392710D769D2Q37621530-4D776D0B-783A-4A52-A892-290AD4E5FABAQ38036687-93B541D9-78DA-4BB3-A466-2CA0CFD847F8Q38156198-DB1F2410-9321-4965-919C-FF21DD273C29Q38296086-669CE2D3-E1CB-4796-9B7C-F9150E48208DQ38671307-4C999858-2404-45C5-9F3C-8BF84C6F2C84Q38702017-24F3331D-B18E-4736-9D1A-1BFD61795B83Q38848322-2DA80DB7-D575-46FD-AAC0-4E4B82A56953Q39219822-15363581-31ED-42BC-A64B-561A04A83518Q39329856-8AD4A134-9D11-4906-ACCE-ADE5C5E2FF95Q39393679-AD73C96F-D4FF-42EF-B346-5172176F7D71Q40042419-5A20D35B-2805-4034-B00B-1AE3CF1FB7ECQ40384316-A4F9DFD8-3066-4CC9-810B-3154538719ACQ41928050-200BFA2B-5C9F-4E70-932D-0117D99FC595Q50034030-F9A92918-1D7D-4ED4-8FE3-49FE90B25470
P2860
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Safety and reactogenicity of c ...... an efficacy trial in Thailand
@ast
Safety and reactogenicity of c ...... an efficacy trial in Thailand
@en
Safety and reactogenicity of c ...... an efficacy trial in Thailand
@en-gb
Safety and reactogenicity of c ...... an efficacy trial in Thailand
@nl
type
label
Safety and reactogenicity of c ...... an efficacy trial in Thailand
@ast
Safety and reactogenicity of c ...... an efficacy trial in Thailand
@en
Safety and reactogenicity of c ...... an efficacy trial in Thailand
@en-gb
Safety and reactogenicity of c ...... an efficacy trial in Thailand
@nl
altLabel
Safety and Reactogenicity of C ...... an Efficacy Trial in Thailand
@en
prefLabel
Safety and reactogenicity of c ...... an efficacy trial in Thailand
@ast
Safety and reactogenicity of c ...... an efficacy trial in Thailand
@en
Safety and reactogenicity of c ...... an efficacy trial in Thailand
@en-gb
Safety and reactogenicity of c ...... an efficacy trial in Thailand
@nl
P2093
P2860
P50
P3181
P1433
P1476
Safety and reactogenicity of c ...... an efficacy trial in Thailand
@en
P2093
Donald P Francis
Donald Stablein
Jeffrey Berenberg
Jittima Dhitavat
Joseph Chiu
Michael Benenson
Patricia Morgan
Pravan Suntharasamai
Punnee Pitisuttithum
Robert J O'Connell
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0027837
P407
P577
2011-01-01T00:00:00Z